Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 2105668

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 2105668

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 182 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 41.26 Billion in 2034 from USD 14.10 Billion in 2025, growing at a CAGR of 12.67 during 2026-2034.This market is witnessing exceptional growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of messenger RNA therapeutics. Contract development and manufacturing organizations provide specialized expertise in process development, analytical testing, formulation, and large-scale production, enabling faster commercialization of innovative therapies. Rising investments in genetic medicine, infectious disease treatments, oncology research, and personalized therapeutics are driving strong market expansion.

CDMOs are investing heavily in advanced manufacturing facilities, lipid nanoparticle technologies, and high-quality production capabilities to meet growing demand. Increasing collaboration between biotechnology innovators and specialized manufacturers is improving production scalability while reducing development timelines. Regulatory expertise, advanced quality systems, and flexible manufacturing capacity are becoming essential competitive advantages. Expanding clinical pipelines and ongoing research into RNA-based medicines continue creating significant growth opportunities.

The future outlook remains highly promising as mRNA technology expands beyond vaccines into treatments for cancer, rare diseases, and chronic conditions. Artificial intelligence-driven process optimization, continuous manufacturing, and automated quality control will improve production efficiency and consistency. Rising pharmaceutical outsourcing and increasing investment in advanced therapeutics will support long-term market development. Continuous innovation will reinforce the strategic importance of mRNA-focused CDMOs worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Application

  • Viral Vaccines
  • Protein Replacement Therapies
  • Cancer Immunotherapies
  • Regenerative Medicine Therapy

By Indication

  • Cancer
  • Infectious Diseases
  • Metabolic and Genetic Diseases
  • Cardiovascular and Cerebrovascular Diseases

By End User

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Government and Academic Research Institutes

COMPANIES PROFILED

  • Thermo Fisher Scientific, Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Rentschler Biopharma, AGC Biologics, Recipharm, Siegfried Holding, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies, Lonza, Curia Global
Product Code: VMR112119302

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Viral Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Protein Replacement Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Cancer Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Regenerative Medicine Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Metabolic and Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Cardiovascular and Cerebrovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Government and Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Application
    • 7.2.2 By Indication
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Application
    • 7.3.2 By Indication
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Application
    • 7.4.2 By Indication
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Application
    • 7.5.2 By Indication
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Application
    • 7.6.2 By Indication
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Thermo Fisher Scientific
    • 9.2.2 Eurofins Scientific
    • 9.2.3 WuXi Biologics
    • 9.2.4 Samsung Biologics
    • 9.2.5 Catalent
    • 9.2.6 Rentschler Biopharma
    • 9.2.7 AGC Biologics
    • 9.2.8 Recipharm
    • 9.2.9 Siegfried Holding
    • 9.2.10 Boehringer Ingelheim
    • 9.2.11 FUJIFILM Diosynth Biotechnologies
    • 9.2.12 Lonza
    • 9.2.13 Curia Global
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!